证券之星消息，12月22日化学制药板块较上一交易日上涨0.28%，康芝药业领涨。当日上证指数报收于 3917.36，上涨0.69%。深证成指报收于13332.73，上涨1.47%。化学制药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日化学制药板块主力资金净流入4250.38万元，游资资金净流出1.77亿元，散户资 金净流入1.34亿元。化学制药板块个股资金流向见下表： ...

（编辑 任世碧） 证券日报网讯 12月22日，奥赛康在互动平台回答投资者提问时表示，基于对公司未来发展前景的坚定 信心，公司聚焦主营业务，秉持全体股东价值最大化的宗旨，以多种方式促进上市公司的可持续发展。 ...

一品红公告称，公司第四届董事会第十五次会议审议通过《关于收到控股股东支持公司发展承诺暨关联 交易的议案》。基于对Arthrosi被并购交易及公司痛风创新药氘泊替诺雷大中华区市场和优先全球供应 的信心，控股股东广润集团将其子公司持有的Arthrosi 9.07%股权（Arthrosi E轮投后估值3.83亿美 元），无偿、无条件给公司，支持创新发展。该事项构成关联交易，已申请豁免提交股东会审议。关联 董事李捍雄、李捍东回避表决，议案获3票同意通过。 ...

Investment Rating - The report maintains a "Neutral" rating for the pharmaceutical and biotechnology industry [1][42]. Core Insights - There is a recovery in demand for clinical research organizations (CROs), while the supply of experimental monkeys is tight, leading to price increases. The domestic financing for innovative drugs is gradually recovering, with a total financing amount of $4.086 billion from January to November 2025, representing a year-on-year increase of 10.6% [1][10]. - The pharmaceutical sector has underperformed compared to the CSI 300 index, with a year-to-date return of 14.49% against the CSI 300's 16.09% [22]. - The current valuation of the pharmaceutical sector is 33.0 times PE based on 2026 profit forecasts, which is a 41% premium over the overall A-share market (excluding financials) [23]. Summary by Sections Recent Trends - The CSI 300 index fell by 0.28% this week, while the pharmaceutical sector decreased by 0.14%, ranking 22nd among 31 primary sub-industries. The weekly performance of sub-sectors includes declines in chemical pharmaceuticals and biological products, while medical services and medical commerce showed gains [9][22]. Market Dynamics - The demand for CROs is recovering, and the supply of experimental monkeys is limited, with prices for 3-5 year old monkeys reaching 140,000 yuan each. This indicates a recovery in the domestic innovative drug research and development environment [10][11]. Valuation - The pharmaceutical sector's current valuation is 29.1 times PE based on trailing twelve months (TTM) earnings, which is below the historical average of 35.0 times PE. The sector has a 17.2% premium over the overall A-share market [23]. Company Performance - Notable performers in the pharmaceutical commercial sector this week include Huaren Health, Luyuan Pharmaceutical, and Shuyuan Pingmin, with significant weekly gains [25]. Key Company Meetings - Upcoming shareholder meetings include Dong'e Ejiao, Zhonghe Holdings, and Yiling Pharmaceutical on December 22, among others [31][32][33].

Core Viewpoint - The company has received approval for the registration certificate of Clomipramine Hydrochloride Tablets, which is used for the treatment of depression, enhancing its product line and market competitiveness [1] Group 1 - The subsidiary, Ningbo Tianheng Pharmaceutical Co., Ltd., has been granted the drug registration certificate by the National Medical Products Administration [1] - The approval of Clomipramine Hydrochloride Tablets will further enrich the subsidiary's product offerings [1] - The production and sales of the new product may be influenced by industry policies and market environment changes, leading to uncertainties regarding its impact on the company's performance [1]

Core Viewpoint - The global competitiveness of Chinese innovative pharmaceutical companies is continuously improving, with a focus on innovation in treatment areas and technology platforms [1] Group 1: Treatment Areas - The commercial health insurance premium scale has significant growth potential and is expected to become a new source of medical payment [1] - Fast-growing treatment areas include cutting-edge technologies such as GLP-1, ADC, and bispecific antibodies [1] - In addition to existing popular fields like oncology and immunology, potential treatment areas to watch include metabolic diseases (e.g., weight loss), chronic diseases (e.g., hypertension, hyperlipidemia), and central nervous system disorders (e.g., Alzheimer's, Parkinson's) [1] Group 2: Technology Platforms - Potential technology platforms to focus on include small nucleic acid drugs, radioactive drugs (RDC), and CAR-T therapies [1] Group 3: Medical Device Industry - The medical device industry is currently under pressure due to policy impacts, but the fundamentals are expected to improve with the ongoing implementation of anti-involution policies, clearing of centralized procurement, and innovation upgrades by companies along with international business expansion [1] Group 4: Investment Products - The Guotai Innovation Pharmaceutical ETF (159377) tracks the Innovation Pharmaceutical Index (399275), which has a daily price fluctuation limit of 20% [1] - This index focuses on the innovative biopharmaceutical sector, selecting listed company securities involved in biopharmaceuticals, chemical pharmaceuticals, and medical services to reflect the overall performance of pharmaceutical companies with high R&D investment and innovation capabilities, leaning towards high-tech and growth styles [1]

Core Insights - The report emphasizes the construction of a strategy portfolio based on industry and thematic ETFs, leveraging insights from previous strategy reports on industry style continuation and switching perspectives [1] - The strategy update indicates a cumulative net return of approximately 0.53% for the period from December 15 to December 19, 2025, with an excess return of about 0.66% compared to the CSI 300 ETF [2][11] - Since October 14, 2024, the strategy has achieved a cumulative return of approximately 26.72%, outperforming the CSI 300 ETF by about 5.86% [2] ETF Holdings and Performance - The report lists various ETFs with their market values and performance, highlighting the following: - Real Estate ETF (3.51 billion) is newly added with a 100% allocation to real estate development, showing a weekly timing signal of -1 [2] - Battery ETF (145.30 billion) continues to be held with a 62.7% allocation, showing a weekly timing signal of 0 [2] - Innovative Energy ETF (12.02 billion) continues to be held with a 46.04% allocation, showing a weekly timing signal of 0 [2] - Consumer Electronics ETF (11.41 billion) is newly added with a 46.5% allocation to semiconductors, showing a weekly timing signal of 0 [2] - Grid Equipment ETF (31.17 billion) continues to be held with an 80.77% allocation, showing a weekly timing signal of 1 [2] - 5G Communication ETF (79.24 billion) is newly added with a 41.2% allocation, showing a weekly timing signal of 1 [2] Weekly Recommendations - For the week of December 22 to December 26, 2025, the report recommends increasing holdings in sectors such as real estate development, batteries, and photovoltaic equipment, while continuing to hold existing positions in battery, innovative energy, and grid equipment ETFs [11]

Core Viewpoint - Shandong Heda has received a significant reduction in anti-dumping and countervailing duties from the U.S. Department of Commerce, which is expected to positively impact the company's financial performance and operational strategy [1][5][9]. Group 1: Anti-Dumping and Countervailing Duties - The final anti-dumping duty rate for Shandong Heda is set at 18.71%, a substantial decrease of 153.53 percentage points from the preliminary ruling [1][5]. - The countervailing duty rate for Shandong Heda is 6.90%, while other Chinese producers face rates ranging from 3.14% to 8.81% [5]. - The initial anti-dumping duty rate was 172.24%, indicating a significant improvement in the final ruling [5][6]. Group 2: Financial Implications - The reduction in duties will lead to a refund of previously paid high guarantee deposits, positively affecting the company's financial results [5][6]. - The sales of hard empty capsules to the U.S. accounted for 62.38% of the total revenue during the investigation period, highlighting the importance of this market for the company [6]. Group 3: Strategic Initiatives - In response to trade barriers, Shandong Heda is accelerating its plans to establish a manufacturing facility in the U.S. as part of its globalization strategy [7][10]. - The company aims to diversify its market presence beyond the U.S., with products already being sold in over 100 countries, including Germany, France, and Japan [10]. - The establishment of a U.S. plant is seen as a critical step to mitigate risks associated with international trade tensions and to enhance market penetration [10].

12月19日，仙琚制药涨0.99%，成交额7938.51万元。两融数据显示，当日仙琚制药获融资买入额568.68 万元，融资偿还1240.07万元，融资净买入-671.39万元。截至12月19日，仙琚制药融资融券余额合计 4.94亿元。 融资方面，仙琚制药当日融资买入568.68万元。当前融资余额4.92亿元，占流通市值的5.41%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，仙琚制药12月19日融券偿还3800.00股，融券卖出300.00股，按当日收盘价计算，卖出金额 2757.00元；融券余量22.53万股，融券余额207.05万元，超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 资料显示，浙江仙琚制药股份有限公司位于浙江省仙居县福应街道现代工业集聚区丰溪西路15号，成立 日期2000年6月26日，上市日期2010年1月12日，公司主营业务涉及甾体原料药和制剂的研制、生产与销 售。主营业务收入构成为：皮质激素63.39%，妇科及计生用药20.69%，其他9.21%，麻醉及肌松用药 6.71%。 截至11月30日，仙琚制药股东户数5.00万，较上期减少1.96%；人均流通股196 ...

据翰宇药业消息，近日，翰宇药业与深圳碳云智肽药物科技有限公司正式达成战略投资合作。根据协议 约定，翰宇药业将以1000万元现金认购碳云智肽新增注册资本，增资完成后持有其0.6623%股权，标志 着双方从前期研发协作迈向资本绑定与产业协同的深度合作阶段。 ...